Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6710-6716

  Lee, Yun Bin ^a,b   Lee, Jeong Hoon ^a   Lee, Dong Hyeon ^a   Cho, Hyeki ^a   Ahn, Hongkeun ^a   Choi, Won Mook ^a   Cho, Young Youn ^a   Lee, Minjong ^a   Yoo, Jeong Ju ^a   Cho, Yuri ^a   Cho, Eun Ju ^a   Yu, Su Jong ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Kim, Chung Yong ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE C; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; TREATMENT RESPONSE; VIRUS STRAIN; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETICS; HEPATITIS B, CHRONIC; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84908635370     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03845-14     Document Type: Article

References (30)

1. Liaw YF. 2006. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther. 11:669-679.
2. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on longterm nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42:121-129. http://dx.doi.org/10.1002/hep.20760.
3. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254-265. http://dx.doi.org/10.1002/hep.21698.
4. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57:167-185. http://dx.doi.org/10.1016/j.jhep.2012.02.010.
5. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
6. Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J. Hepatol 56(Suppl 1):S112-S122. http://dx.doi.org/10.1016/S0168-8278(12)60012-9.
7. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712. http://dx.doi.org/10.1002/hep.21290.
8. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32: 1078-1088. http://dx.doi.org/10.1053/jhep.2000.19619.
9. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791. http://dx.doi.org/10.1053/jhep.2001.27563.
10. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696. http://dx.doi.org/10.1086/368083.
11. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722. http://dx.doi.org/10.1053/j.gastro.2003.09.033.
12. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P. 2012. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J. Hepatol. 56:520-526. http://dx.doi.org/10.1016/j.jhep.2011.09.018.
13. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80. http://dx.doi.org/10.1002/hep.23246.
14. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254. http://dx.doi.org/10.1136/gut.2010.223206.
15. Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. 2013. Efficacy of adefovir-based combination therapy for patients with lamivudine-And entecavirresistant chronic hepatitis B virus infection. Antimicrob. Agents Chemother. 57:6325-6332. http://dx.doi.org/10.1128/AAC.01742-13.
16. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. 2010. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J. Clin. Microbiol. 48:3641-3647. http://dx.doi.org/10.1128/JCM.01306-10.
17. Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C. 2009. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J. Viral Hepat. 16:279-285. http://dx.doi.org/10.1111/j.1365-2893.2009.01074.x.
18. Rosenbaum PR, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55. http://dx.doi.org/10.1093/biomet/70.1.41.
19. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. 2007. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med. Care 45:S103-S107. http://dx.doi.org/10.1097/MLR.0b013e31806518ac.
20. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 48:747-755. http://dx.doi.org/10.1016/j.jhep.2008.01.027.
21. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 44:283-290. http://dx.doi.org/10.1016/j.jhep.2005.10.018.
22. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451. http://dx.doi.org/10.1053/j.gastro.2007.08.079.
23. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313. http://dx.doi.org/10.1002/hep.21534.
24. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. 2014. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146:980-988. http://dx.doi.org/10.1053/j.gastro.2013.12.028.
25. Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin. Gastroenterol. Hepatol., in press.
26. Shaw T, Bartholomeusz A, Locarnini S. 2006. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44:593-606. http://dx.doi.org/10.1016/j.jhep.2006.01.001.
27. Zoulim F. 2011. Hepatitis: treatment failure in chronic hepatitis B. Nat. Rev. Gastroenterol. Hepatol. 8:366-367. http://dx.doi.org/10.1038/nrgastro.2011.104.
28. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J. 2002. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 40:1331-1333. http://dx.doi.org/10.1053/ajkd.2002.36924.
29. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO. 2009. Tenofovir-Associated renal and bone toxicity. HIV Med. 10:482-487. http://dx.doi.org/10.1111/j.1468-1293.2009.00716.x.
30. Gracey DM, Snelling P, McKenzie P, Strasser SI. 2013. Tenofovir-Associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir. Ther. 18:945-948. http://dx.doi.org/10.3851/IMP2649.